Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale. Last year's report highlighted some companies that have since made an even bigger impact in biotech as a whole, including the newly public Bind Therapeutics and hot RNAi specialist Alnylam. You'll see familiar names in both the industry and the academic realm in this year's report, among others that have offered important developments to the arena. Check out the report >>
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.
Like the tiny organelles used to propel some bacteria, artificial cilia developed by German engineers could someday help deliver drugs.
Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.
Researchers have found a way to use nanoparticles to deliver drugs that can "wake up" the immune system and fortify its natural response to harmful cancer cells in the body.
Researchers at the National University of Singapore have developed a method for delivering the polypeptide antibiotic actinomycin D with modified, self-assembled DNA nanopyramid against bacteria such as E. coli and Staphylococcus aureus, the bug causes staph infections.
On the heels of FDA's rejection of the AcelRx New Drug Application for sublingually delivered postoperative pain killer Zalviso, CEO Richard King expounded on the "optical system errors" of the opioid drug's handheld, preprogrammed delivery device during a July 28 conference call with investors.
From Our Sister Sites
In this week's EuroBiotech Report, the last week of July was a massive one for European biotech IPOs, with BioBlast Pharma, Innocoll, Macrocure, Mapi Pharma and VBL Therapeutics all heading to the Nasdaq. All of the companies struggled though. And more.
HeartWare International is facing FDA ire for its ventricular assist system, but regulatory pushback hasn't seemed to put a damper on earnings. The company charted double-digit growth during the second quarter, fueled in part by record sales for its signature device in domestic and international markets.